Stock PRTC PURETECH HEALTH PLC
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases PureTech Health plc

Equities

PRTC

GB00BY2Z0H74

Market Closed - London S.E.
Other stock markets
 11:35:11 2024-05-24 am EDT 		5-day change 1st Jan Change
227.5 GBX +0.89% Intraday chart for PureTech Health plc +3.41% +17.15%
May. 21 PureTech-founded Vedanta begins trials for VE303 colonic bacteria drug AN
May. 20 PureTech Health Opens $100 Million Buyback Program MT

Press Releases

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PureTech to Present at the Jefferies Global Healthcare Conference
BU
PureTech Founded Entity Vedanta Biosciences Enrolls First Patient in Pivotal Phase 3 RESTORATiVE303 Study of VE303 for the Prevention of Recurrent C. difficile Infection
BU
PureTech Health: Launch of Proposed $100 Million Tender Offer at 250 Pence Per Ordinary Share
BU
PureTech Health : Shareholder Circular regarding Proposed Tender Offer
PU
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry Annual Meeting
AQ
PureTech Founded Entity Seaport Therapeutics Presents Data from Multiple SPT-300 Trials at Society of Biological Psychiatry (SOBP) Annual Meeting
BU
PureTech Founded Entity Seaport Therapeutics Adds Industry Veteran to Board of Directors and Makes Key Executive Appointments
BU
PureTech Health : Proxy Form for 2024 AGM
PU
PureTech Health : Notice of Meeting for 2024 AGM
PU
PureTech Announces Annual Results for Year Ended December 31, 2023
BU
PureTech Health plc - Notice of Results
AQ
PureTech Health: Notice of Results
BU
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 in Idiopathic Pulmonary Fibrosis
AQ
PureTech Announces Completion of Enrollment in Phase 2b ELEVATE IPF Trial of LYT-100 (Deupirfenidone) in Idiopathic Pulmonary Fibrosis
BU
PureTech Receives FDA Fast Track Designation for LYT-200 in Head and Neck Cancers
BU
Seaport Therapeutics Launches with $100 Million Oversubscribed Series a Financing Round to Advance Novel Neuropsychiatric Medicines
AQ
PureTech Launches Seaport Therapeutics with $100 Million Oversubscribed Series A and Announces Management Transitions
BU
PureTech Proposes $100 Million Capital Return
BU
Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion
BU
PureTech Receives Orphan Drug Designation for LYT-200 in Acute Myeloid Leukemia
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PRTC Stock
  4. News PureTech Health plc
  5. Press Releases